REG - Genflow Biosciences - Board Changes

Genflow BiosciencesAnnouncement

29/06/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220629:nRSc6017Qa&default-theme=true

RNS Number : 6017Q  Genflow Biosciences PLC  29 June 2022

 

PRESS RELEASE

29 June 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

 

Board Changes

Genflow (LSE: GENF) is pleased to announce that Tamara Joseph and Dr
Guy-Charles Fanneau de la Horie will join the Board as Independent
Non-Executive Directors with immediate effect.

Ms Tamara Joseph

Tamara, a US resident, has extensive experience in both early-stage and
commercial biotech companies in the US. Her expertise, within the biotech
sector, includes public and private financings, M&A, global expansions and
a Nasdaq uplisting. She has also supported Nasdaq financings in excess of
$800m.

Her experience, spanning over 20 years, includes acting as a member of the
executive team (as Chief Legal Officer and General Counsel) at multiple US
publicly listed companies. Tamara is currently serving as Chief Legal Officer
at Nasdaq listed, pharmaceutical firm, Spero Therapeutics Inc., a multi-asset,
clinical-stage biopharmaceutical company. She previously served as Chief Legal
Officer at Nasdaq listed, Millendo Therapeutics Inc., to support its
transition to a publicly traded company, and as General Counsel at Enzyvant
Therapeutics Inc., a rare disease company focused on regenerative medicine
which is now a subdivision of Sumitomo Pharma.

Previously, Tamara has served as an adviser to the boards of five US publicly
traded biotechs, including Cubist Pharmaceuticals Inc. (that was acquired by
global healthcare leader, Merck & Co).

She currently holds two board and advisory roles with Heluna Health PHFE
("Heluna"), a Los Angeles based, leading fiscal sponsor for US public health
programmes; and Boston based therapeutic non-profit organisation, BINA Farm.
Within Heluna, Tamara is a member of its Executive Committee and Governance
Committee.

Tamara's appointment reflects Genflow's aim of strengthening its presence in
the US, where the longevity sector has gained enormous attention and attracted
significant investment capital in excess of $3bn last year following
investments made by high profile, ultra-high-net-worth individuals.

Dr Guy-Charles Fanneau de la Horie

Over the past 20 years, Guy-Charles has built, and led, biotech executive
teams where he has acted as Chief Executive Officer.

During his tenures, he has successfully led IPOs and completed multiple
fundraisings. Guy-Charles' expertise in the biotech field in both public and
private companies encompasses launching and selling new drugs in untapped
markets, with successful early access programs.

Specifically, Guy-Charles has served as Chief Executive Officer at three
biotech companies, including, until very recently, Euronext Growth traded,
Pherecydes Pharma, a biotech company that develops treatments against
resistant bacterial infections; and Neovacs, a therapeutic vaccine company.

Guy-Charles has also held senior positions at Biogen, a Nasdaq listed global
biotechnology company.

Guy-Charles managed the IPO and associated successful financing of Neovacs in
2010, and in 2021, led Pherecydes Pharma through an oversubscribed placing.

Genflow Growth

Both of these new appointments will greatly support the Company's growth and
deeply strengthen and enhance the capital markets experience at board level.
Importantly, and specifically, for the Company, the appointments will furnish
the Board with broad and relevant experience of US listed biotech companies.

Following the appointment of Tamara and Guy-Charles, the total number of
Directors on Genflow's Board will consist of four Independent Non-Executive
Directors (including the Chairman), and one Executive Director.

Resignations

The Company also announces that Dr Gabrielle Silver, Independent Non-Executive
Director, is stepping down from the Board owing to her time commitments and to
focus on her other board roles.  In addition,  Professor Andrew Scott, is
also stepping down as a Non-Executive Director in order to devote more time to
his research and writing, aimed at raising awareness around longevity more
broadly amongst the public and policymakers. The Board would like to take this
opportunity to thank Gabrielle and Andrew for their valuable contribution to
the Company over the course of Genflow's listing journey and landmark IPO.

Dr Eric Leire, Founder and CEO of Genflow, said: "We are delighted and indeed,
honoured, to announce that Tamara Joseph and Dr Guy-Charles Fanneau de la
Horie are joining the Genflow board. Tamara's outstanding track record in
biotechnology, with particular exposure to listed firms in the US, dovetails
with Genflow's growing exposure in the US following our recent distinguished
collaborations with institutions such as the University of Rochester's Aging
Research Center (RoAR). In addition, Guy-Charles' expertise in the
biotechnology field and in capital markets specifically, will be an invaluable
asset for Genflow as the Company continues to grow and perform against its
stated strategy.

Finally, on behalf of the board, I would also like to thank Gabrielle and
Andrew for their commitment and for the support they have provided to Genflow
on its journey to become the first longevity biotechnology firm to list in
Europe."

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker                    +44 203 869 6086

 Jonathan Critchley                  +44 203 897 0981

 Keith Swann
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno-associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

-Ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABKCBPPBKKQAB